Iannitto, E., Ferrero, S., Bommier, C., Drandi, D., Ferrante, M., Bouabdallah, K., et al. (2024). Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. HAEMATOLOGICA, 109(7), 2297-2302 [10.3324/haematol.2023.284109].
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Iannitto, Emilio
;Mancuso, Salvatrice;Tripodo, Claudio;
2024-07-01
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
11509-Article Text-83751-2-10-20240626.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
4.01 MB
Formato
Adobe PDF
|
4.01 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
